The clinical research of sequential moxifloxacin therapy in elder patients with community acquired pneumonia

Objective To evaluate the efficacy,safety and cost of sequential moxifloxacin therapy in elder patients with community acquired pneumonia compared with moxifloxacin injection.Methods 70 elder patients with community acquired pneumonia were randomly divided into two groups,moxifloxacin injection followed by tablet(sequential group) and moxifloxacin injection group(control group).In sequential group,moxifloxacin was given by intravenous infusion 400 mg/250 ml,once daily for 5~7 days,followed by oral administration at the same dose.In control group,moxifloxacin was administered by intravenous infusion,400 mg/250 ml,once daily.The total treatment duration of two groups was also 14 days.Results After treatment,the effective rate for the sequential group was 91.43%,while for the control group was 94.29%.There was no statistically significant difference between the two groups(P0.05).The bacterial eradication rate in the two groups was 88.24%,and 87.50% respectively.There was also no significant difference between the two group(P0.05).The average cost per patient and the incidence of adverse drug reaction of the sequential group was lower than the control group.Conclusion The sequential moxifloxacin therapy for CAP is safe,effective,and cost-saved compared with full-course moxifloxacin infusion.